A Phase I Safety and Immunogenicity Trial of UBI SynVac (HIV-1 MN Octameric V3 Peptide Vaccine)

Inclusion Criteria Subjects must have: * Normal history and physical exam. * Negative for HIV by ELISA within 6 weeks of immunization. * CD4 count \>= 400 cells/mm3. * Normal urinalysis. Exclusion Criteria Co-existing Condition: Subjects with the following conditions are excluded: * Medical or psychiatric condition or occupational responsibilities that preclude compliance. * Active syphilis (volunteers are eligible if serology is documented to be a false positive or due to a remote (\> 6 months) treated infection). * Active tuberculosis (volunteers with a positive PPD and normal chest x-ray showing no evidence of TB and not requiring INH therapy are eligible). * Hepatitis B surface antigenemia. Subjects with the following prior conditions are excluded: * History of immunodeficiency, chronic illness, autoimmune disease, or use of immunosuppressive medications. * History of anaphylaxis or other serious adverse reactions to vaccines. Prior Medication: Excluded: * Live attenuated vaccines within the past 60 days. NOTE: Medically indicated subunit or killed vaccines (e.g., influenza, pneumococcal) are permitted if received at least 2 weeks prior to first immunization. * Experimental agents within the past 30 days. * Prior HIV vaccines. Prior Treatment: Excluded: * Blood products or immunoglobulin within the past 6 months. Identifiable high-risk behavior for HIV infection, including history of injection drug use within the last 12 months prior to enrollment and higher or intermediate risk sexual behavior.